Thoracic Oncology Program
Experience, Surgical Excellence, and Outstanding Multidisciplinary Care

Study Suggests Molecular Assay More Accurate in NSCLC Risk Assessment
Woodard Jablons Mann Slideshow
Building on
earlier retrospective validation studies, a team of Thoracic Oncology Program researchers, led by David M. Jablons, M.D.Michael Mann, M.D., and lead author Gavitt Woodard, M.D., demonstrated in a small prospective study the clinical utility of a 14-gene expression assay in stratifying risk among NSCLC patients.    Read more >
Test Guides Treatment for Earliest-Stage Patients

A molecular test developed by physician-scientists at UCSF may better predict post-operative mortality in early-stage lung cancer patients. Building on earlier work, the group identified a group of post-operative patients withᅠthe earliest stage of lung cancerᅠwho had a high likelihood of recurrence.

New Lung Cancer Test More Accurately Predicts Survival
Jablons Talk On Gene Final2

In the two largest ever clinical studies on the molecular genetics of lung cancer, an international team, led by thoracic surgeonsᅠDavid M. Jablons, M.D.ᅠ(left),ᅠMichael Mann, M.D.,ᅠand Johannes Kratz, M.D., a former surgical resident,ᅠshowed a molecular test better predicted death from early-stage lung cancer than conventional staging.

Thoracic Oncology Logo Final -PrintLung cancer is the leading cause of cancer death worldwide and the Thoracic Oncology Program is poised to conquer it. UCSF provides state-of-the-art care to patients with lung cancer, mesothelioma, esophageal cancer, sarcoma and cancer that has metastasized to the chest. The program is led by David M. Jablons, M.D., Chief of the Section of General Thoracic Surgery and Program Leader of the Thoracic Oncology Program. Patients receive treatment from a dedicated multidisciplinary team of specialists. At UCSF, one of the world's leading biomedical research centers, patients also have access to clinical trials for promising new drugs.